Vaccine compositions for eliciting an immune response against N-

Details Vaccine compositions for eliciting an immune response against N- Vaccine compositions for eliciting an immune response against N-

1998-04-17

2000-11-21

Wortman, Donna C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Cancer cell or component thereof

4241841, 4241371, 424422, 424423, 4242831, 4242781, 4241941, 4242341, 4241411, 4241551, 4241561, 4241741, 5303875, 5303897, 530395, 530806, 530828, 5303877, 5303881, 514 42, 514 25, 514885, A61K 3900

Patent

active

061499218

ABSTRACT:
The invention provides novel uses for n-glycolylated gangliosides and N-acetylated gangliosides, or derivatives and/or oligosaccharides thereof The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumor cells.

REFERENCES:
patent: 4950750 (1990-08-01), Ogawa et al.
patent: 5026557 (1991-06-01), Estis et al.
patent: 5102663 (1992-04-01), Livingston et al.
patent: 5449610 (1995-09-01), Lillehoj
patent: 5591772 (1997-01-01), Lane et al.
patent: 5788985 (1998-08-01), Rodriguez et al.
Dohi et al., "An IgG.sub.3 Monoclonal Antibody Established after Immunization with G.sub.M3 Lactone:Immunochemical Specificity and Inhibition of Melanoma Cell Growth in Vitro and in Vivo", Cancer Research, vol. 48, pp. 5680-5685, 1988.
Furukawa et al., "Analysis of the Expression of N-Glycolylneuraminic Acid-containing Gangliosides in Cells and Tissue using Two Human Monoclonal Antibodies", The Journal of Biological Chemistry, vol. 263, No. 34, pp. 18507-18512, 1988.
Hamiltion et al., "Ganglioside Expression On Human Malignant Melanoma Assessed By Quantitative Immune Thin-Layer Chromatography", Int. J. Cancer, 53, pp. 566-573, 1993.
Helling et al., "G.sub.M2 -KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21", Cancer Research 55, pp. 2783-2788, Jul. 1, 1995.
Livingston et al., "Characterization of IgG and IgM Antibodies Induced in Melanoma Patients by Immunization with Purified G.sub.M2 Ganglioside", Cancer Research 49, pp. 7045-7050, Dec. 15, 1989.
Livingston et al., "GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3", Vaccine, vol. 11, Issue 12, pp. 1199-1204, 1993.
Portoukalian et al., "Humoral Immune Response in Disease-Free Advanced Melanoma Patients After Vaccination with Melanoma-Associated Gangliosides", International Journal of Cancer 49, pp. 893-899, 1991.
Vogel F.R. and M.F. Powell. Compendium of Vaccine Adjuvants and Excipients. Plenum Publishing Corporation. New York, NY. 1994 ;p. 47, 1994.
Livingston et al, Cancer Research 49:7045-7050, 1989.
Carlsson et al., "Protein Thiolation and Reversible Protein-Protein Conjugation", Biochem. J., 173, pp. 723-737, 1978.
Hakomori et al., "Isolation and Characterization of Glycosphingolipid from Animal Cells and Their Membranes", Methods in Enzymology, vol. 32, pp. 345-367, 1974.
Helling et al., "G.sub.D3 Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccines", Cancer Research 54, pp. 197-203, Jan. 1, 1994.
Livingston et al., "Approaches to Augmenting the IgG Antibody Response to Melanoma Ganglioside Vaccines", Annals New York Academy of Sciences, pp. 204-213.
Livingston, Philip O., "Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside-KLH Conjugate Vaccines", Immunological Reviews, No. 145, pp. 147-166, 1995.
Margalit et al., "Prediction of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence", The Journal of Immunology, vol. 138, pp. 2213-2229, No. 7, Apr. 1, 1987.
Marquina et al., "Gangliosides Expressed in Human Breast Cancer", Cancer Research 56, pp. 5165-5171, 1996.
Sonnino et al., "Recognition by Two-Dimensional Thin Layer Chromatography and Densitometric Quantification of Alkali-Labile Gangliosides from the Brain of Different Animals", Analytical Biochemistry 128, pp. 104-114, 1983.
Stroll et al., "Improved procedure for the construction of neoglycolipids having antigenic and lectin-binding activities, from reducing oligosaccharides", Biochem. J. 256, pp. 661-664, 1988.
Svennerholm, Lars, "Quantitative Estimation of Sialic Acids", Biochem. Biophys. ACTA, vol. 24, pp. 604-611, 1957.
Zopf et al., "Affinity Purification of Antibodies Using Oligosaccharide-Phenethylamine Derivatives Coupled to Sepharose", Methods Enzymol., pp. 171-175, 1978.

Affiliated with

Also associated with

Rating

Vaccine compositions for eliciting an immune response against N- does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine compositions for eliciting an immune response against N-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine compositions for eliciting an immune response against N- will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1254320